<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03553914</url>
  </required_header>
  <id_info>
    <org_study_id>PLM60-MC-1201</org_study_id>
    <nct_id>NCT03553914</nct_id>
  </id_info>
  <brief_title>PLM60 for Peripheral T Cell Lymphoma (PTCL)</brief_title>
  <official_title>A Randomized Phase 1-2 Study of PLM60 in Patients With Peripheral T-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Conjupro Biotherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Conjupro Biotherapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1-2, randomized, multicenter, open label study of PLM60 administered via&#xD;
      intravenous (IV) infusion in 28 day treatment cycles to adult participants with relapsed or&#xD;
      refractory Peripheral T Cell Lymphoma (PTCL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to identify and characterize the safety, tolerability, efficacy, and&#xD;
      the PK profile of PLM60 in patients with relapsed or refractory PTCL. Phase 1 will explore&#xD;
      multiple dose levels and select a single dose level in Phase 2 to more effectively assess&#xD;
      efficacy in the PTCL population.&#xD;
&#xD;
      It is anticipated that up to approximately 30 participants will be enrolled during Phase 1.&#xD;
      The actual number enrolled, however, will depend on the number of dose-limiting toxicity&#xD;
      (DLT)-evaluable participants that complete the first cycle of therapy. Phase 2 will enroll up&#xD;
      to 34 participants at the RP2D, some of whom will have been enrolled during Phase 1.&#xD;
&#xD;
      Consequently, up to approximately 55 participants will be treated in the study as a whole.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    IND Inactive Status&#xD;
  </why_stopped>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects experiencing AEs and SAEs after treatment with PLM60</measure>
    <time_frame>8 Months</time_frame>
    <description>Percentage of subjects experiencing AEs and SAEs, by evaluating physical examinations, vital signs, ECOG score, ECGs, ECHO or MUGA scans, and clinical laboratory findings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate in patients with PTCL after treatment PLM60</measure>
    <time_frame>19 months</time_frame>
    <description>Assessing the overall response rate (ORR) by Lugano Classification</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Peripheral T Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>12 mg/m^2 dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive PLM60 at 12 mg/m^2 dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>16 mg/m^2 dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive PLM60 at 16 mg/m^2 dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg/m^2 dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive PLM60 at 20 mg/m^2 dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLM60</intervention_name>
    <description>PLM60 will be administered via intravenous infusion in 28-day cycles for up to 7 cycles.</description>
    <arm_group_label>12 mg/m^2 dose group</arm_group_label>
    <arm_group_label>16 mg/m^2 dose group</arm_group_label>
    <arm_group_label>20 mg/m^2 dose group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent prior to study-related procedures&#xD;
&#xD;
          2. Patients with histologically confirmed relapsed or refractory PTCL, who were treated&#xD;
             with at least 2 lines of standard therapy and for whom there is no known effective&#xD;
             therapy.&#xD;
&#xD;
          3. Recovered from all toxicity from prior anticancer therapy based on clinical&#xD;
             evaluation/ judgement of the Investigator&#xD;
&#xD;
          4. Participants must have an Eastern Cooperative Oncology Group (ECOG) performance score&#xD;
             of 0-2.&#xD;
&#xD;
          5. Participants who have sufficient baseline organ function by laboratory evaluations&#xD;
&#xD;
          6. Left ventricular ejection fraction (LVEF) ≥ 50%&#xD;
&#xD;
          7. Life expectancy ≥ 16 weeks&#xD;
&#xD;
          8. Women of childbearing potential must have a negative pregnancy test prior to study&#xD;
             entry, and agree to use adequate contraception from study entry through at least 3&#xD;
             months after the last dose of study drug&#xD;
&#xD;
          9. A male participant must agree to use adequate contraception; or female sexual partner&#xD;
             who uses adequate contraception measures from study entry through at least 3 months&#xD;
             after the last dose of study drug&#xD;
&#xD;
        Additional Inclusion Criteria for Phase 2:&#xD;
&#xD;
          1. Involved lymph nodes or masses should be measurable in at least 2 perpendicular&#xD;
             dimensions and be ≥ 1.5 cm in the longest of the perpendicular dimensions (based on&#xD;
             Lugano Classification)&#xD;
&#xD;
          2. Agree to undergo pretreatment bone marrow biopsy and post treatment bone marrow biopsy&#xD;
             when required to confirm response&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Participants with a history of allergy to anthracyclines or liposomal drugs&#xD;
&#xD;
          2. Prior treatment with mitoxantrone, any anthracycline, or anthacenedione&#xD;
&#xD;
          3. Treatment with doxorubicin (with the exception of pegylated liposomal doxorubicin)&#xD;
             with a total cumulative dose &gt; 300 mg/m2, or epirubicin with a total cumulative dose &gt;&#xD;
             500 mg/m2&#xD;
&#xD;
          4. Investigational treatment within 4 weeks of the start of PLM60&#xD;
&#xD;
          5. Prior allogeneic stem cell transplantation&#xD;
&#xD;
          6. Current symptomatic (uncontrolled) central nervous system tumor involvement&#xD;
&#xD;
          7. Certain types of cardiac impairment as defined in the protocol at the time of&#xD;
             enrolment&#xD;
&#xD;
          8. Any concurrent active malignancy or concurrent malignancy diagnosis with less than 12&#xD;
             months disease free interval&#xD;
&#xD;
          9. Participants with evidence of an active infection&#xD;
&#xD;
         10. Participants with active bleeding&#xD;
&#xD;
         11. Participants who have had organ transplants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Officials</last_name>
    <role>Study Director</role>
    <affiliation>Conjupro Biotherapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrial Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Li C, Cui J, Wang C, Li Y, Zhang H, Wang J, Li Y, Zhang L, Zhang L, Guo W, Wang Y. Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy. Eur J Pharm Biopharm. 2008 Oct;70(2):657-65. doi: 10.1016/j.ejpb.2008.05.019. Epub 2008 Jun 6.</citation>
    <PMID>18582570</PMID>
  </reference>
  <reference>
    <citation>Yang J, Shi Y, Li C, Gui L, Zhao X, Liu P, Han X, Song Y, Li N, Du P, Zhang S. Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy. Cancer Chemother Pharmacol. 2014 Sep;74(3):637-46. doi: 10.1007/s00280-014-2523-8. Epub 2014 Jul 18.</citation>
    <PMID>25034977</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 1, 2018</study_first_submitted>
  <study_first_submitted_qc>May 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2018</study_first_posted>
  <last_update_submitted>October 14, 2020</last_update_submitted>
  <last_update_submitted_qc>October 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

